The prepared BSA-loaded nanoparticles were washed and redispersed in PBS containing 0.03% w/v sodium azide to get a nanoparticle concentration 5–6 mg ml−1. The washed IFN-β-loaded nanoparticles were suspended in human blood plasma (1 mg ml−1). The release medium was replaced after sampling. The samples were mixed by a rotating mixer (Bio RS-24 mini-Rotator, Biosan, Latvia) with vertical rotation at 30 rpm, and incubated at 37 °C in a G24 Environmental Incubator Shaker (New Brunswick Scientific, USA). At predetermined intervals, 0.5 ml of each sample was ultracentrifuged (Beckman Optima Max-E) for 10 min at 40 000×g. The concentration of released IFN-β was determined using ELISA. The BSA concentration was followed by mBCA assay in the supernatant after removal of the nanoparticles by centrifugation, and the IFN-β was analysed in the removed supernatants by ELISA using a multiplate reader.
Bio rs 24 mini rotator
The Bio RS-24 mini-Rotator is a laboratory equipment designed for gentle and uniform mixing of samples. It features a compact and portable design, accommodating up to 24 microtubes or 12 test tubes. The rotator operates at a fixed speed of 30 rpm, providing a consistent and controlled mixing motion.
2 protocols using bio rs 24 mini rotator
Investigating IFN-β Decomposition Kinetics
The prepared BSA-loaded nanoparticles were washed and redispersed in PBS containing 0.03% w/v sodium azide to get a nanoparticle concentration 5–6 mg ml−1. The washed IFN-β-loaded nanoparticles were suspended in human blood plasma (1 mg ml−1). The release medium was replaced after sampling. The samples were mixed by a rotating mixer (Bio RS-24 mini-Rotator, Biosan, Latvia) with vertical rotation at 30 rpm, and incubated at 37 °C in a G24 Environmental Incubator Shaker (New Brunswick Scientific, USA). At predetermined intervals, 0.5 ml of each sample was ultracentrifuged (Beckman Optima Max-E) for 10 min at 40 000×g. The concentration of released IFN-β was determined using ELISA. The BSA concentration was followed by mBCA assay in the supernatant after removal of the nanoparticles by centrifugation, and the IFN-β was analysed in the removed supernatants by ELISA using a multiplate reader.
In Vitro Drug Release Characterization of Nanocomposites
The sorafenib-loaded nanocomposite was subjected to biorelevant in vitro drug release experiments, that is, after their washing, 10 mg nanocomposites were re-suspended in 15 ml human blood plasma containing 0.03% sodium azide bactericide. The NPs in release medium were incubated at 37°C in G24 Environmental Incubator Shaker (New Brunswick Scientific Co. Inc., USA) and shaken by BIO RS-24 Mini-rotator (Biosan, Latvia) for 2 days at 700 rpm. At predetermined intervals, 0.5 ml of each sample was centrifuged (Hermle Z216 MK microcentrifuge, Germany) for 20 min at 15,000 rpm, washed three times and the gained nanoparticles were dissolved in 0.5 ml ethanol. The sorafenib concentration was analyzed after HPLC separation as described above.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!